<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medsovet-7636</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НОВОСТИ. ОТКРЫТИЯ И СОБЫТИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEWS, DISCOVERIES AND EVENTS</subject></subj-group></article-categories><title-group><article-title>Александр Лила:  «У врача всегда есть возможность выбрать оптимальный  генно-инженерный биологический препарат для лечения  пациента с ревматоидным артритом»</article-title><trans-title-group xml:lang="en"><trans-title>Alexander Lila:  “The doctor always has an option to choose  the optimal genetically engineered biological drug  to treat a patient with rheumatoid arthritis”</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>21</day><month>07</month><year>2023</year></pub-date><volume>0</volume><issue>10</issue><fpage>15</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Редакционная с.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/7636">https://www.med-sovet.pro/jour/article/view/7636</self-uri><abstract><p>Интервью с директором ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой», заведующим кафедрой ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, доктором медицинских наук, профессором, членом-корреспондентом РАН Александром Михайловичем Лила.</p></abstract><trans-abstract xml:lang="en"><p>Interview with Alexander M. Lila, Dr. of Sci. (Med.), Professor, Director of Federal State Budgetary Scientific Institution V.A. Nasonova Research Institute of Rheumatology, Head of Department of Rheumatology, Russian Medical Academy of Continuing Postgraduate Education, Corresponding Member of the Russian Academy of Sciences.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
